Aller au contenu
Trouver un autre spécialiste

Michel Boutin

Professeur associé, Faculté de médecine et des sciences de la santé
FMSS Département de pédiatrie

Présentation

Sujet de recherche

Dépistage prénatal et néonatal, Maladies génétiques, Molécules organiques et biomolécules, Maladie de Parkinson

Disciplines de recherche

Chimie, Biochimie

Mots-clés

Spectrométrie de masse, Métabolomique

Intérêts de recherche

Découverte de biomarqueurs par spectrométrie de masse

Langues parlées et écrites

Anglais, Français

Diplômes

(2009). Analysis and validation of biomarkers for respiratory diseases and graft versus host disease (GVHD) (Postdoctorat, Spectrométrie de masse/Métabolomique).

(2006). Study of the effect of an enzyme on the proteins of cancer cells (Postdoctorat, Spectrométrie de masse/Protéomique).

(2005). Monitoring of workers exposure to air contaminants in car repair shops (Postdoctorat, Spectrométrie de masse/Santé et sécurité au travail). McGill University.

(2005). Identification et quantification des isocyanates générés lors de la dégradation thermique d'une peinture automobile à base de polyuréthane (Doctorat, Ph. D. Chimie). Université de Montréal.

(1998). (Baccalauréat, B.Sc. Chimie). Université de Sherbrooke.

Titres de compétence

Adjunct professor/Department of Pediatrics. Université de Sherbrooke.

Chemist.

Habilitated for codirection of masters and doctoral students for the Nuclear Sciences and Biomedical Imaging program. Université de Sherbrooke.

Habilitated for codirection of masters and doctoral students in the biochemistry and functional genomics program. Université de Sherbrooke.

Researcher.

Prix et distinctions

  • (2007) Postdoctoral Scholarship. Conseil de recherches en sciences naturelles et en génie (CRSNG). (Distinction).
  • (2007) Postdoctoral Scholarship. Fonds de recherche du Québec - Nature et technologies (FRQNT). (Distinction).
  • (2004) Ph. D. Scholarship. Fonds de recherche du Québec - Nature et technologies (FRQNT). (Distinction).
  • (2004) Ph. D. Scholarship. Institut de recherche Robert-Sauvé en santé et en sécurité du travail. (Distinction).
  • (2004) Ph. D. Scholarship at workplace. Fonds pour la Formation de Chercheurs et l'Aide à la Recherche (FCAR-MRST). (Distinction).
  • (2004) Ph. D. Scholarship in research. Conseil de recherches en sciences naturelles et en génie (CRSNG). (Distinction).
  • (2002) M.Sc. Scholarship in research. Conseil de recherches en sciences naturelles et en génie (CRSNG). (Distinction).
  • (2001) M.Sc. Scholarship. Institut de recherche Robert-Sauvé en santé et en sécurité du travail. (Distinction).
  • (2001) M.Sc. Scholarship in research. Fonds pour la Formation de Chercheurs et l'Aide à la Recherche (FCAR). (Distinction).
  • (1997) Undergraduate Scholarship in research. Conseil de recherches en sciences naturelles et en génie (CRSNG). (Distinction).
  • American Biltrite Scholarship. Université de Sherbrooke. (Distinction).
  • American Biltrite Scholarship. Université de Sherbrooke. (Distinction).
  • American Biltrite Scholarship. Université de Sherbrooke. (Distinction).
  • First prize: Oral presentation. Association québécoise pour l'hygiène, la santé et la sécurité du travail (AQHSST). (Prix / Récompense).
  • First prize: Oral presentation in French. Concordia University. (Prix / Récompense).
  • First prize: Poster presentation. Colloque thématique de l'IRSST portant sur les mutations des milieux de travail. (Prix / Récompense).
  • Third prize: Article writting. Revue travail et Santé. (Prix / Récompense).
  • Travel Bursary for 5th Update on Nephropathy (Mexico City, Mexico). Kidney for Life. (Distinction).
  • Welcome Scholarship (M.Sc.). Université de Montréal. (Distinction).

Publications

Articles de revue

  • Limgala RP , Jennelle T , Plassmeyer M , Boutin M , Lavoie P , Abaoui M , Auray-Blais C , Nedd K , Alpan O , Goker-Alpan O. (2019). Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta. American journal of translational research 11 (3), 1683-1696. (Article publié).
  • Menkovic I , Lavoie P , Boutin M , Auray-Blais C. (2019). Distribution of heparan sulfate and dermatan sulfate in mucopolysaccharidosis type II mouse tissues pre- and post-enzyme-replacement therapy determined by UPLC-MS/MS. Bioanalysis 11 (8), 727-740. (Article publié).
  • Auray-Blais C , Lavoie P , Abaoui M , Côté AM , Boutin M , Akbari A , Levin A , Mac-Way F , Tr Clarke J. (2019). High-Risk Screening for Fabry Disease in a Canadian Cohort of Chronic Kidney Disease Patients. Clinica chimica acta; international journal of clinical chemistry (Article publié).
  • Lenders M , Stappers F , Niemietz C , Schmitz B , Boutin M , Ballmaier PJ , Zibert A , Schmidt H , Brand SM , Auray-Blais C , Brand E. (2019). Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. Journal of medical genetics 56 (8), 548-566. (Article publié).
  • Menkovic I , Marchand AS , Boutin M , Auray-Blais C. (2019). Neonatal Mass Urine Screening Approach for Early Detection of Mucopolysaccharidoses by UPLC-MS/MS. Diagnostics (Basel, Switzerland) 9 (4), (Article publié).
  • Martineau T , Boutin M , Côté AM , Maranda B , Bichet DG , Auray-Blais C. (2019). Tandem mass spectrometry analysis of urinary podocalyxin and podocin in the investigation of podocyturia in women with preeclampsia and Fabry disease patients. Clinica chimica acta; international journal of clinical chemistry 495 67-75. (Article publié).
  • Alharbi FJ , Baig S , Rambhatla SB , Vijapurapu R , Auray-Blais C , Boutin M , Steeds R , Wheeldon N , Dawson C , Geberhiwot T. (2019). The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of fabry disease. Clinica chimica acta; international journal of clinical chemistry (Article publié).
  • Toupin A , Lavoie P , Arthus MF , Abaoui M , Boutin M , Fortier C , Ménard C , Bichet DG , Auray-Blais C. (2018). Analysis of globotriaosylceramide (Gb3) isoforms/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography/tandem mass spectrometry. Analytica chimica acta 1015 35-49. (Article publié).
  • Yogasundaram H , Nikhanj A , Putko BN , Boutin M , Jain-Ghai S , Khan A , Auray-Blais C , West ML , Oudit GY. (2018). Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association 7 (21), e009098. (Article publié).
  • Alharbi FJ , Baig S , Auray-Blais C , Boutin M , Ward DG , Wheeldon N , Steed R , Dawson C , Hughes D , Geberhiwot T. (2018). Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease. Journal of inherited metabolic disease 41 (2), 239-247. (Article publié).
  • Nelson MP , Boutin M , Tse TE , Lu H , Haley ED , Ouyang X , Zhang J , Auray-Blais C , Shacka JJ. (2018). The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein. Neurobiology of disease 110 68-81. (Article publié).
  • Auray-Blais C , Lavoie P , Boutin M , Ntwari A , Hsu TR , Huang CK , Niu DM. (2017). Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation. Clinica chimica acta; international journal of clinical chemistry 466 185-193. (Article publié).
  • Huang J , Khan A , Au BC , Barber DL , López-Vásquez L , Prokopishyn NL , Boutin M , Rothe M , Rip JW , Abaoui M , Nagree MS , Dworski S , Schambach A , Keating A , West ML , Klassen J , Turner PV , Sirrs S , Rupar CA , Auray-Blais C , Foley R , Medin JA. (2017). Cells for Correction of Fabry Disease. Molecular therapy. Methods & clinical development 5 241-258. (Article publié).
  • Auray-Blais C , Lavoie P , Boutin M , Abaoui M. (2017). High-Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb3 ) in Urine Collected on Filter Paper. Current protocols in human genetics 93 17.26.1-17.26.12. (Article publié).
  • Boutin M , Menkovic I , Martineau T , Vaillancourt-Lavigueur V , Toupin A , Auray-Blais C. (2017). Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients. Analytical chemistry 89 (24), 13382-13390. (Article publié).
  • Shestakova EA , Boutin M , Bourassa S , Bonneil E , Bijl JJ. (2017). [Identification of proteins associated with transcription factors HOXA9 and E2A-PBX1 by tandem affinity purification]. Molekuliarnaia biologiia 51 (3), 490-501. (Article publié).
  • Auray-Blais C , Lavoie P , Maranda B , Boutin M. (2016). Evaluation of urinary keratan sulfate disaccharides in MPS IVA patients using UPLC-MS/MS. Bioanalysis 8 (3), 179-91. (Article publié).
  • Lavoie P , Boutin M , Abaoui M , Auray-Blais C. (2016). Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry. Current protocols in human genetics 90 17.22.1-17.22.12. (Article publié).
  • Kamani MA , Provençal P , Boutin M , Pacienza N , Fan X , Novak A , Huang TC , Binnington B , Au BC , Auray-Blais C , Lingwood CA , Medin JA. (2016). Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion. Future science OA 2 (4), FSO147. (Article publié).
  • Abaoui M , Boutin M , Lavoie P , Auray-Blais C. (2016). High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb3 Isoforms Using Tandem Mass Spectrometry. Current protocols in human genetics 91 17.24.1-17.24.11. (Article publié).
  • Battista MC , Boutin M , Venne P , Blais L , Bérard A , Lacroix M , Patenaude J , Guillemette L , Cossette B , Hivert MF , Auray-Blais C. (2016). Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood. Bioanalysis 8 (14), 1441-1450. (Article publié).
  • Provençal P , Boutin M , Dworski S , Au B , Medin JA , Auray-Blais C. (2016). Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry. Bioanalysis 8 (17), 1793-807. (Article publié).
  • Boutin M , Sun Y , Shacka JJ , Auray-Blais C. (2016). Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease. Analytical chemistry 88 (3), 1856-63. (Article publié).
  • Boutin M , Lavoie P , Abaoui M , Auray-Blais C. (2016). Tandem Mass Spectrometry Quantitation of Lyso-Gb3 and Six Related Analogs in Plasma for Fabry Disease Patients. Current protocols in human genetics 90 17.23.1-9. (Article publié).
  • Abaoui M , Boutin M , Lavoie P , Auray-Blais C. (2016). Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients. Clinica chimica acta; international journal of clinical chemistry 452 191-8. (Article publié).
  • Boutin M , Auray-Blais C. (2015). Metabolomic discovery of novel urinary galabiosylceramide?analogs as Fabry disease biomarkers. Journal of the American Society for Mass Spectrometry 26 (3), 499-510. (Article publié).
  • Auray-Blais C , Blais CM , Ramaswami U , Boutin M , Germain DP , Dyack S , Bodamer O , Pintos-Morell G , Clarke JT , Bichet DG , Warnock DG , Echevarria L , West ML , Lavoie P. (2015). Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clinica chimica acta; international journal of clinical chemistry 438 195-204. (Article publié).
  • Ferreira S , Auray-Blais C , Boutin M , Lavoie P , Nunes JP , Martins E , Garman S , Oliveira JP. (2015). Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. Clinica chimica acta; international journal of clinical chemistry 447 96-104. (Article publié).
  • Boutin M , Auray-Blais C. (2014). Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb?-related analogues in Fabry disease. Analytical chemistry 86 (7), 3476-83. (Article publié).
  • Dupont FO , Gagnon R , Boutin M , Auray-Blais C. (2013). A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers. Current medicinal chemistry 20 (2), 280-8. (Article publié).
  • Manwaring V , Boutin M , Auray-Blais C. (2013). A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients. Analytical chemistry 85 (19), 9039-48. (Article publié).
  • Lavoie P , Boutin M , Auray-Blais C. (2013). Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry. Analytical chemistry 85 (3), 1743-52. (Article publié).
  • Boutin M , Gagnon R , Lavoie P , Auray-Blais C. (2012). LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease. Clinica chimica acta; international journal of clinical chemistry 414 273-80. (Article publié).
  • Auray-Blais C , Boutin M. (2012). Novel Gb(3) isoforms detected in urine of fabry disease patients: a metabolomic study. Current medicinal chemistry 19 (19), 3241-52. (Article publié).
  • Gagné JP , Pic E , Isabelle M , Krietsch J , Ethier C , Paquet E , Kelly I , Boutin M , Moon KM , Foster LJ , Poirier GG. (2012). Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress. Nucleic acids research 40 (16), 7788-805. (Article publié).
  • Auray-Blais C , Boutin M , Gagnon R , Dupont FO , Lavoie P , Clarke JT. (2012). Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics. Analytical chemistry 84 (6), 2745-53. (Article publié).
  • Boutin M , Berthelette C , Gervais FG , Scholand MB , Hoidal J , Leppert MF , Bateman KP , Thibault P. (2009). High-sensitivity nanoLC-MS/MS analysis of urinary desmosine and isodesmosine. Analytical chemistry 81 (5), 1881-7. (Article publié).
  • Boutin M , Ahmad I , Jauhiainen M , Lachapelle N , Rondeau C , Roy J , Thibault P. (2009). NanoLC-MS/MS analyses of urinary desmosine, hydroxylysylpyridinoline and lysylpyridinoline as biomarkers for chronic graft-versus-host disease. Analytical chemistry 81 (22), 9454-61. (Article publié).
  • Boutin M , Bich C , Afonso C , Fournier F , Tabet JC. (2007). Negative-charge driven fragmentations for evidencing zwitterionic forms from doubly charged coppered peptides. Journal of mass spectrometry : JMS 42 (1), 25-35. (Article publié).
  • Boutin M , Dufresne A , Ostiguy C , Lesage J. (2006). Determination of airborne isocyanates generated during the thermal degradation of car paint in body repair shops. The Annals of occupational hygiene 50 (4), 385-93. (Article publié).
  • Boutin M , Lesage J , Ostiguy C , Pauluhn J. (2005). Validation of a solvent-free sampler for the determination of low molecular weight aliphatic isocyanates under thermal degradation conditions. Journal of occupational and environmental hygiene 2 (9), 456-61. (Article publié).
  • Boutin M , Lesage J , Ostiguy C , Bertrand MJ. (2004). Approche systémique visant l'identification et la quantification des isocyanates émis lors de la combustion d'une peinture automobile. Travail et Santé 20 (3), 35-39. (Article publié).
  • Boutin M , Lesage J , Ostiguy C , Bertrand MJ. (2004). Identification of the isocyanates generated during the thermal degradation of a polyurethane car paint. Journal of Analytical and Applied Pyrolysis 71 (2), 791-802. (Article publié).
  • Boutin M , Lesage J , Ostiguy C , Bertrand MJ. (2004). Temperature-programmed pyrolysis hyphenated with metastable atom bombardment ionization mass spectrometry (TPPy/MAB-MS) for the identification of additives in polymers. Journal of the American Society for Mass Spectrometry 15 (9), 1315-9. (Article publié).
  • Boutin M , Lesage J , Ostiguy C , Bertrand MJ. (2003). Comparison of EI and metastable atom bombardment ionization for the identification of polyurethane thermal degradation products. Journal of Analytical and Applied Pyrolysis 70 (2), 505-517. (Article publié).
  • Boutin M , Lesage J , Ostiguy C , Bertrand MJ. (2003). Investigating the thermal degradation of polymers: a systematic approach. Applied occupational and environmental hygiene 18 (10), 724-8. (Article publié).
  • Boutin M. (2001). Alerte au feu. Dire: La revue des cycles supérieurs de l'Université de Montréal 11 (1), 24-25. (Article publié).

Autres contributions

Cours enseignés

  • Biomarker Discovery and Translational Research Leading to Clinical Utility: Experimental Approaches and Pitfalls. (2019-09-26 à 2019-09-26).Mass Spectrometry: Applications to the Clinical Lab (MSACL). Niveau : Niveau supérieur.
  • Spectrométrie de masse/Applications en santé. RBL-740. (2013-01-08).Université de Sherbrooke. Canada.
  • Génomique fonctionnelle et santé. BMO-7009. (2011-09-01 à 2011-12-16).Université Laval. Canada.
  • Analyse de traces par méthodes instrumentales. CHI-7101. (2005-09-01 à 2005-12-16).Université du Québec à Montréal. Canada.
  • Méthodes Instrumentales. CHI-2104. (2005-09-01 à 2005-12-16).Université du Québec à Montréal. Canada.
  • Analyses de traces par méthodes instrumentales. CHI-7101. (2003-09-01 à 2004-12-17).Université du Québec à Montréal. Canada.

Gestion d'évènements

  • Co-organizer. Symposium de spectrométrie de masse (biennal). (Conférence).

Présentations

  • (2019). Simple and Rapid Tandem Mass Spectrometry Method for the Analysis of Methylmalonic Acid in Urine. Mass Spectrometry: Applications to the Clinical Lab (MSACL). Salzburg, Autriche
  • (2019). Tandem Mass Spectrometry Analysis of Urinary Methylmalonic Acid as Marker of Metabolic Vitamin B12 Deficiency in Older Adults. 15th International Conference of the Metabolomics Society. The Haye, Pays-Bas
  • (2018). Discovery of novel galabiosylceramide-related biomarkers of Fabry disease by semi-targeted metabolomics: The complex issue of structural isomer interférences. Mass Spectrometry: Applications to the Clinical Lab (MSACL). Salzburg, Autriche
  • (2018). Structural Isomer Interferences in the Context of Precision Medicine: Efficacy of Galabiosylceramide as a Fabry disease biomarker. 14th International Conference of the Metabolomics Society. Seattle, États-Unis
  • (2018). Urinary Galabiosylceramide (Ga2): An Efficient Biomarker for Fabry Disease Patients with Residual Enzyme Activity. 1er Symposium canadien sur les maladies lysosomales. Sherbrooke, Canada
  • (2017). Evaluation of the distribution of Gb3 isoforms and analogues in Fabry mouse tissues using a tandem mass spectrometry approach. 5th Nephropathy Update. Mexico, Mexique
  • (2017). Tandem mass spectrometry analysis of Gb3 isoforms and analogues in different NOD/SCID Fabry mouse tissues. 13rd Annual International Conference of the Metabolomics Society. Brisbane, Australie
  • (2016). Fabry disease biomarkers: From discovery to clinical use. 99th Canadian Chemistry Conference and Exhibition/Human health and diagnostics symposium. Halifax, Canada
  • (2016). UPLC-MS/MS analysis of glucosylceramide and galactosylceramide isoforms in Parkinson’s disease brain tissues. 12nd Annual International Conference of the Metabolomics Society. Dublin, Irlande
  • (2015). Biomarker discovery and translational research leading to clinical utility. Metabolomic Symposium/Centre de recherche du CHU. Quebec, Canada
  • (2015). Discovery of novel urinary galabiosylceramide-related biomarkers for Fabry disease using a Q-Tof mass spectrometry metabolomic approach. 63rd ASMS Conference on Mass Spectrometry and Allied Topics. Saint-Louis, États-Unis
  • (2015). Mass spectrometry analysis of alpha-galactosidase A metabolites, globotriaosylceramide and globotriaosylsphingosine, in Parkinson disease brain tissues. 11st Annual International Conference of the Metabolomics Society. San Francisco, États-Unis
  • (2015). Metabolomic discovery of novel urinary galabiosylceramide analogs as Fabry disease biomarkers. 15th Annual LSD Club. Banff, Canada
  • (2014). Discovery of galabiosylceramide-related Fabry disease urinary biomarkers using a mass spectrometry-based metabolomic approach. 10th Annual International Conference of the Metabolomics Society. Tsuruoka, Japon
  • (2013). 13C16-palmitic acid metabolization into ceramide for the determination of ceramide synthesis in type 2 diabetes patients. 9th Annual International Conference of the Metabolomics Society. Glasgow, Royaume-Uni
  • (2013). A metabolomic study reveals novel Gb3 analogues in urine of Fabry patients. 9th Annual WORLD Symposium. Orlando, États-Unis
  • (2013). Discovery of Fabry disease biomarkers using a Q-TOF metabolomic approach. Waters Open House. Brossard, Canada
  • (2012). Novel Fabry disease biomarkers detected by a time-of-flight mass spectrometry approach. 60th ASMS Conference on Mass Spectrometry and Allied Topics. Vancouver, Canada
  • (2012). Quantitative analysis of ceramides in urines and plasma of Fabry patients. 8th WORLD Symposium. San Diego, États-Unis
  • (2011). Systematic profiling of the dynamic composition of poly(ADP-ribose)-containing protein complexes. 7th International Barbados Proteomics Conference, A Chromosome-Based Human Proteome Project and Cell Biology Proteomics Application Workshop. Holetown, Barbade
  • (2009). NanoLC-MS/MS analysis of urinary biomarkers of chronic graft-versus-host disease. 57th ASMS Conference on Mass Spectrometry and Allied Topics. Philadelphia, États-Unis
  • (2008). High sensitivity nano-LC-MS/MS analysis of urinary hydroxylysylpyridinoline and lysylpyridinoline as measurement of collagen turnover. 56th ASMS Conference on Mass Spectrometry and Allied Topics. Denver, États-Unis
  • (2007). High sensitivity analysis of urinary desmosine and isodesmosine using Nano-LC-MS/MS. 55th ASMS Conference on Mass Spectrometry and Allied Topics. Indianapolis, États-Unis
  • (2006). Comportement des complexes peptide/cuivre(II) en phase gazeuse: mise en évidence de zwitterions. 23ièmes Journées Françaises de Spectrométrie de Masse. Nante, France